JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
University Medical Center Hamburg-Eppendorf
Hamburgo, AlemaniaPublicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (23)
2023
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
2021
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Leukemia, Vol. 35, Núm. 1, pp. 31-44
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
-
First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2013
2012
-
How to manage neutropenia in multiple myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 12, Núm. 1, pp. 5-11
2011
-
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
Blood
-
Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
Blood
-
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
Blood, Vol. 118, Núm. 17, pp. 4519-4529
-
Reply to A. Gratwohl
Journal of Clinical Oncology
2010
2008
-
Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation
Haematologica, Vol. 93, Núm. 9, pp. 1343-1350
-
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Haematologica, Vol. 93, Núm. 3, pp. 431-438